Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Change in Acquisitions & Divestments (2016 - 2025)

Historic Change in Acquisitions & Divestments for Arrowhead Pharmaceuticals (ARWR) over the last 15 years, with Q4 2025 value amounting to $115.3 million.

  • Arrowhead Pharmaceuticals' Change in Acquisitions & Divestments fell 239.98% to $115.3 million in Q4 2025 from the same period last year, while for Dec 2025 it was $686.8 million, marking a year-over-year increase of 6083.26%. This contributed to the annual value of $689.6 million for FY2025, which is 5590.36% up from last year.
  • According to the latest figures from Q4 2025, Arrowhead Pharmaceuticals' Change in Acquisitions & Divestments is $115.3 million, which was down 239.98% from $101.8 million recorded in Q3 2025.
  • Over the past 5 years, Arrowhead Pharmaceuticals' Change in Acquisitions & Divestments peaked at $240.5 million during Q2 2025, and registered a low of $13.1 million during Q1 2021.
  • Its 5-year average for Change in Acquisitions & Divestments is $96.6 million, with a median of $85.9 million in 2023.
  • As far as peak fluctuations go, Arrowhead Pharmaceuticals' Change in Acquisitions & Divestments skyrocketed by 31471.97% in 2021, and later crashed by 4640.02% in 2023.
  • Over the past 5 years, Arrowhead Pharmaceuticals' Change in Acquisitions & Divestments (Quarter) stood at $38.3 million in 2021, then surged by 81.39% to $69.4 million in 2022, then soared by 92.31% to $133.5 million in 2023, then fell by 11.48% to $118.2 million in 2024, then decreased by 2.4% to $115.3 million in 2025.
  • Its Change in Acquisitions & Divestments stands at $115.3 million for Q4 2025, versus $101.8 million for Q3 2025 and $240.5 million for Q2 2025.